{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T02:18:40Z","timestamp":1772936320585,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Dual\u2010antiplatelet therapy (DAPT) and proton pump inhibitor (PPI) are frequently prescribed after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) placement. However, studies that evaluate the optimal PPI when used as primary prevention in patients without a history of peptic ulcer disease or upper gastrointestinal bleeding (UGIB), particularly in the context of DAPT involving prasugrel, are lacking. This study aimed to assess the efficacy and safety of PPI use in preventing UGIB in this patient population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included patients who underwent PCI with coronary stent placement for acute coronary syndrome or stable angina at our institution from January 2015 to December 2020. Eligible patients started DAPT with aspirin and prasugrel and concomitantly received PPI therapy (lansoprazole or esomeprazole), with a follow-up period of two years. The primary endpoint was UGIB incidence, diagnosed during follow-up, serving as an efficacy measure. Secondary endpoints included the assessment of major bleeding (as defined by the Thrombolysis in Myocardial Infarction major bleeding criteria) and clinically relevant non-major bleeding events. Safety outcomes focused on adverse event incidence attributable to PPI use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 165 patients analyzed, 109 and 56 were included in the lansoprazole and esomeprazole groups, respectively, with cumulative incidence of UGIB at 96\u00a0weeks of 0.9% (1\/109) and 3.6% (2\/56). No significant differences in terms of major bleeding events or other bleeding outcomes were observed between the two groups. Adverse events related to PPI use were reported as diarrhea\/soft stools in 7 (6%) cases and thrombocytopenia in 1 (1%) case in the lansoprazole group, whereas no such events were observed in the esomeprazole group. No clinically significant hematologic or biochemical abnormalities were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study evaluated the efficacy and safety of PPIs in combination with DAPT, including prasugrel, following PCI, and suggests that lansoprazole and esomeprazole may offer comparable efficacy in preventing UGIB.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-024-00398-y","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:50:19Z","timestamp":1732524619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study"],"prefix":"10.1186","volume":"10","author":[{"given":"Yutaro","family":"Ide","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-5707","authenticated-orcid":false,"given":"Go","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyohei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuko","family":"Okazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"398_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1253\/circj.CJ-19-1109","volume":"84","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, Kosuge M, Shinke T, Nakagawa Y, Natsuaki M, Yasuda S, Akasaka T, Kohsaka S, Haze K, Hirayama A. JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease. Circ J. 2020;84:831\u201365. https:\/\/doi.org\/10.1253\/circj.CJ-19-1109.","journal-title":"Circ J"},{"key":"398_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"36","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP. COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;36:1909\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1007964.","journal-title":"N Engl J Med"},{"key":"398_CR3","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.jacc.2015.12.068","volume":"67","author":"M Vaduganathan","year":"2016","unstructured":"Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP. COGENT Investigators. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016;67:1661\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.068.","journal-title":"J Am Coll Cardiol"},{"key":"398_CR4","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O\u2019Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082\u2013115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513.","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"398_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"2018","author":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, J\u00fcni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, J\u00fcni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;2018(39):213\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419.","journal-title":"Eur Heart J"},{"issue":"83","key":"398_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","volume":"2019","author":"Kazuo Kimura, Takeshi Kimura, Masaharu Ishihara, Yoshihisa Nakagawa, Koichi Nakao, Katsumi Miyauchi, Tomohiro Sakamoto, Kenichi Tsujita, Nobuhisa Hagiwara, Shunichi Miyazaki, Junya Ako, Hirokuni Arai, Hideki Ishii, Hideki Origuchi, Wataru Shimizu, Hirofumi Takemura, Yoshio Tahara, Yoshihiro Morino, Kenji Iino, Tomonori Itoh, Yoshitaka Iwanaga, Keiji Uchida, Hirohisa Endo, Ken Kongoji, Kenji Sakamoto, Hiroki Shiomi, Takao Shimohama, Atsushi Suzuki, Jun Takahashi, Ichiro Takeuchi, Akihito Tanaka, Toshihiro Tamura, Takahiro Nakashima, Teruo Noguchi, Daisuke Fukamachi, Tomohiro Mizuno, Junichi Yamaguchi, Kenji Yodogawa, Masami Kosuge, Shun Kohsaka, Hideaki Yoshino, Satoshi Yasuda, Hiroaki Shimokawa, Atsushi Hirayama, Takashi Akasaka, Kazuo Haze, Hisao Ogawa, Hiroyuki Tsutsui, Tsutomu Yamazaki, on behalf of the Japanese Circulation Society Joint Working Group. JCS","year":"2018","unstructured":"Kazuo Kimura, Takeshi Kimura, Masaharu Ishihara, Yoshihisa Nakagawa, Koichi Nakao, Katsumi Miyauchi, Tomohiro Sakamoto, Kenichi Tsujita, Nobuhisa Hagiwara, Shunichi Miyazaki, Junya Ako, Hirokuni Arai, Hideki Ishii, Hideki Origuchi, Wataru Shimizu, Hirofumi Takemura, Yoshio Tahara, Yoshihiro Morino, Kenji Iino, Tomonori Itoh, Yoshitaka Iwanaga, Keiji Uchida, Hirohisa Endo, Ken Kongoji, Kenji Sakamoto, Hiroki Shiomi, Takao Shimohama, Atsushi Suzuki, Jun Takahashi, Ichiro Takeuchi, Akihito Tanaka, Toshihiro Tamura, Takahiro Nakashima, Teruo Noguchi, Daisuke Fukamachi, Tomohiro Mizuno, Junichi Yamaguchi, Kenji Yodogawa, Masami Kosuge, Shun Kohsaka, Hideaki Yoshino, Satoshi Yasuda, Hiroaki Shimokawa, Atsushi Hirayama, Takashi Akasaka, Kazuo Haze, Hisao Ogawa, Hiroyuki Tsutsui, Tsutomu Yamazaki, on behalf of the Japanese Circulation Society Joint Working Group. JCS. Guideline on Diagnosis and Treatment of Acute Coronary Syndrome. Circ J. 2018;2019(83):1085\u2013196. https:\/\/doi.org\/10.1253\/circj.CJ-19-0133.","journal-title":"Circ J"},{"key":"398_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354\u201362. https:\/\/doi.org\/10.1056\/NEJMoa0809171.","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"398_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1365-2036.1999.00022.x","volume":"13","author":"T Ishizaki","year":"1999","unstructured":"Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors\u2013emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27\u201336. https:\/\/doi.org\/10.1046\/j.1365-2036.1999.00022.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"398_CR9","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","volume":"5","author":"JT Brandt","year":"2007","unstructured":"Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429\u201336. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02775.x.","journal-title":"J Thromb Haemost"},{"key":"398_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003824","volume":"5","author":"LR Jackson 2nd","year":"2016","unstructured":"Jackson LR 2nd, Peterson ED, McCoy LA, Ju C, Zettler M, Baker BA, Messenger JC, Faries DE, Effron MB, Cohen DJ, Wang TY. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. J Am Heart Assoc. 2016;5: e003824. https:\/\/doi.org\/10.1161\/JAHA.116.003824.","journal-title":"J Am Heart Assoc"},{"key":"398_CR11","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482.","journal-title":"N Engl J Med"},{"key":"398_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/apt.15059","volume":"49","author":"CG Guo","year":"2019","unstructured":"Guo CG, Chen L, Chan EW, Cheung KS, Isshiki T, Wong ICK, Leung WK. Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y12 inhibitors compared with clopidogrel. Aliment Pharmacol Ther. 2019;49:7\u201319. https:\/\/doi.org\/10.1111\/apt.15059.","journal-title":"Aliment Pharmacol Ther"},{"key":"398_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1253\/circj.CJ-18-0956","volume":"83","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Kozuma K, Kitazono T, Iizuka T, Sekine T, Shiosakai K, Usui I, Kogure S. Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II) - A 3-Month Interim Analysis of a Postmarketing Observational Study. Circ J. 2019;83:637\u201346. https:\/\/doi.org\/10.1253\/circj.CJ-18-0956.","journal-title":"Circ J"},{"key":"398_CR14","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1253\/circj.CJ-20-0253","volume":"84","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Kitazono T, Kozuma K, Sekine T, Nakamura S, Shiosakai K, Tanabe A, Iizuka T. Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II) - Final 2-Year Follow-up Results of a Postmarketing Observational Study. Circ J. 2020;84:1981\u20139. https:\/\/doi.org\/10.1253\/circj.CJ-20-0253.","journal-title":"Circ J"},{"key":"398_CR15","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/S0140-6736(00)02816-6","volume":"356","author":"O Blatchford","year":"2000","unstructured":"Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet. 2000;356:1318\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(00)02816-6.","journal-title":"Lancet"},{"key":"398_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"398_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.14309\/ajg.0000000000001134","volume":"116","author":"JE Kurlander","year":"2021","unstructured":"Kurlander JE, Barnes GD, Sukul D, Helminski D, Kokaly AN, Platt K, Gurm H, Saini SD. Trials of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Lack Strategies to Ensure Appropriate Gastroprotection. Am J Gastroenterol. 2021;116:821\u20134. https:\/\/doi.org\/10.14309\/ajg.0000000000001134.","journal-title":"Am J Gastroenterol"},{"key":"398_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjoq-2022-001956","volume":"11","author":"T Jinadu","year":"2022","unstructured":"Jinadu T, Radhakrishnan A, Fan L. Improving use of proton pump inhibitors with dual antiplatelet therapy in patients admitted with acute coronary syndrome. BMJ Open Qual. 2022;11: e001956. https:\/\/doi.org\/10.1136\/bmjoq-2022-001956.","journal-title":"BMJ Open Qual"},{"key":"398_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.dld.2022.10.018","volume":"55","author":"O Sneh-Arbib","year":"2023","unstructured":"Sneh-Arbib O, Ben-Shitrit S, Weisman YL, Koshnir S, Levi Z, Calivarysky B. Using an algorithm to assess the rate and trend over time of inappropriate proton pump inhibitors prescription upon hospital discharge. Dig Liver Dis. 2023;55:485\u20139. https:\/\/doi.org\/10.1016\/j.dld.2022.10.018.","journal-title":"Dig Liver Dis"},{"key":"398_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/MEG.0000000000001125","volume":"30","author":"MY Khan","year":"2018","unstructured":"Khan MY, Siddiqui WJ, Alvarez C, Aggarwal S, Hasni SF, Ahmad A, Eisen H. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:847\u201353. https:\/\/doi.org\/10.1097\/MEG.0000000000001125.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"398_CR21","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/jth.13316","volume":"14","author":"D Alexopoulos","year":"2016","unstructured":"Alexopoulos D, Xanthopoulou I, Deftereos S, Hamilos M, Sitafidis G, Kanakakis I, Pentara I, Vavouranakis M, Davlouros P, Hahalis G, Goudevenos J. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. J Thromb Haemost. 2016;14:1146\u201354. https:\/\/doi.org\/10.1111\/jth.13316.","journal-title":"J Thromb Haemost"},{"key":"398_CR22","doi-asserted-by":"publisher","unstructured":"Shi W, Ni L, Yang J, Fan X, Yu M, Yang H, Yu M, Yang Y. The Clinical Impact of Proton Pump Inhibitors When Co-Administered With Dual Antiplatelet Therapy in Patients Having Acute Myocardial Infarction With Low Risk of Gastrointestinal Bleeding: Insights From the China Acute Myocardial Infarction Registry. Front Cardiovasc Med. 2021;8:685072. https:\/\/doi.org\/10.3389\/fcvm.2021.685072.","DOI":"10.3389\/fcvm.2021.685072"},{"key":"398_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128004","volume":"10","author":"AA Lambert","year":"2015","unstructured":"Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0128004. https:\/\/doi.org\/10.1371\/journal.pone.0128004.","journal-title":"PLoS ONE"},{"key":"398_CR24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamainternmed.2015.42","volume":"175","author":"EG McDonald","year":"2015","unstructured":"McDonald EG, Milligan J, Frenette C, Lee TC. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Intern Med. 2015;175:784\u201391. https:\/\/doi.org\/10.1001\/jamainternmed.2015.42.","journal-title":"JAMA Intern Med"},{"key":"398_CR25","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3109\/0886022X.2015.1057800","volume":"37","author":"W Cheungpasitporn","year":"2015","unstructured":"Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, O\u2019Corragain OA, Korpaisarn S, Erickson SB. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237\u201341. https:\/\/doi.org\/10.3109\/0886022X.2015.1057800.","journal-title":"Ren Fail"},{"key":"398_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016;176:238\u201346. https:\/\/doi.org\/10.1001\/jamainternmed.2015.7193.","journal-title":"JAMA Intern Med"},{"key":"398_CR27","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1248\/yakushi.130.1743","volume":"130","author":"T Yasu","year":"2010","unstructured":"Yasu T, Ikee R, Miyasaka Y, Chubachi H, Saito S. Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study. Yakugaku Zasshi. 2010;130:1743\u201350. https:\/\/doi.org\/10.1248\/yakushi.130.1743.","journal-title":"Yakugaku Zasshi"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00398-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-024-00398-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00398-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:02:10Z","timestamp":1732525330000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-024-00398-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1186\/s40780-024-00398-y","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Hokushin General Hospital (Receipt No. 2023003). Written informed consent was waived and the information was disclosed in an opt-out manner using a document posted in our hospital, where the option to withdraw from this study was also provided.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}